Quantcast
Last updated on April 24, 2014 at 5:30 EDT

Latest Breast cancer treatment Stories

2012-08-20 02:31:39

IRVINE, Calif. and AMSTERDAM, Aug. 20, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced that it has been granted the International Organization for Standardization (ISO) 13485 certification for all activities at their facilities in Irvine and Amsterdam. Agendia has been a leader in maintaining the highest quality standards and operating in compliance with FDA GMP QSR, CLIA, CAP, OSHA and the CE Mark as well...

2012-08-16 00:42:15

The presence of multiple ovarian cancer genomes in an individual patient and the absence or downregulation of the gene LRP1B are associated with the development of chemoresistance in women with the high-grade serous cancer subtype of ovarian cancer whose disease recurs after primary treatment. These study results are published in Cancer Research, a journal of the American Association for Cancer Research. David Bowtell, Ph.D., head of the Cancer Genomics and Genetic Program at the Peter...

2012-08-13 14:23:15

SUNNYVALE, Calif., Aug. 13, 2012 /PRNewswire/ -- A European cancer center of excellence, Ospedale Borgo Trento in Verona, Italy, recently published a study of 226 women with early-stage breast cancer that received a single dose of Intra-Operative Electron Radiation Therapy (IOERT) using the IntraOp Medical Corporation Mobetron® (OTC: IOPD) during surgery to remove their breast tumor. There was only one local recurrence after a mean follow-up of almost four years. The study was...

2012-08-13 06:24:41

MEMPHIS, Tenn., Aug. 13, 2012 /PRNewswire-USNewswire/ -- The West Clinic Comprehensive Breast Center is pleased to welcome Richard E. Fine, MD, FACS, one of the nation's leading board certified breast surgeons to its premier team which includes Michael P. Berry, MD, FACS, and Roy M. Oswaks, MD. As former Director of Advanced Breast Care in Atlanta, Georgia, Dr. Fine is an innovative pioneer in the diagnosis and treatment of breast diseases with extensive experience in new breast biopsy...

2012-08-10 02:23:10

CHICAGO, Aug. 10, 2012 /PRNewswire-USNewswire/ -- "Having a compassionate team of care providers" is the most important experience factor among cancer patients when rating their overall satisfaction with their care experience according to a new study conducted by Healthgrades, the leading provider of information to help consumers make informed decisions about physicians and hospitals. The national survey of more than 1,400 U.S. cancer patients was conducted online during between January and...

2012-08-08 10:25:16

REDWOOD CITY, Calif., Aug. 8, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended June 30, 2012. Total revenue increased to $57.6 million in the second quarter of 2012, compared with $50.8 million in 2011, an increase of 13 percent. Product revenue was $57.2 million in the second quarter of 2012, compared with $50.5 million for the same period in 2011, an increase of 13 percent. Net...

shutterstock_108653990
2012-08-07 07:21:42

Connie K. Ho for redOrbit.com - Your Universe Online 90 percent. This is the percentage of solid cancer patients who have gradual resistance to chemotherapy, according to BBC News. Researchers recently revealed that chemotherapy, a treatment for cancer, could possibly damage healthy cells and trigger a protein that would strengthen tumor resistance and growth. Chemotherapy is described as a treatment that can stop reproduction of fast-dividing cells and is given in various dosages....

2012-08-02 22:21:21

New treatment option extends median survival time by more than 6 months Postmenopausal women with the most common type of metastatic breast cancer now have a new treatment option that lengthens their lives, according a study led by UC Irvine oncologist Dr. Rita Mehta and conducted by the Southwest Oncology Group. The findings appear in the Aug. 2 issue of the New England Journal of Medicine. A combination of the two anti-estrogen drugs anastrozole and fulvestrant extended the median...

2012-08-02 22:18:40

Study published in New England Journal of Medicine A study co-authored by a Loyola researcher and published in the New England Journal of Medicine is offering new hope to women with advanced breast cancer. The study found that combing two drugs that normally are each given as single agents significantly extended the lives of women with metastatic breast cancer. Kathy Albain, MD, a breast cancer specialist at Loyola University Medical Center, is among the main authors of the study....

2012-08-01 15:01:00

Scientists at Western University have identified a new therapeutic target for advanced breast cancer which has shown tremendous promise in mouse models. The study led by Lynne-Marie Postovit of Western's Schulich School of Medicine & Dentistry looked at a protein called Nodal that is primarily found in embryonic or stem cells. Postovit discovered high levels of this protein in aggressive breast cancer tumors. Nodal was found to promote vascularization in the tumor, providing nutrients and...